MBHB attorney Taylor Weilnau analyzes the Supreme Court oral arguments in the Hikma v. Amarin case in Bloomberg Law, IAM, and Law360. She argues that the creation a broad safe harbor from infringement for generic drugmakers that use skinny labels is unlikely, based on the arguments.